Cancer and ageing: Convergent and divergent mechanisms

Nature Reviews Molecular Cell Biology

Volumn 8, Issue 9, 2007, Pages 715-722

  Serrano, Manuel ^a   Blasco, Maria A ^a  

^a Centro Nacional de Investigaciones Oncológicas   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

AGING; CANCER; CANCER RESISTANCE; CARCINOGENESIS; CELL DAMAGE; CELL DEATH; CELL MEMBRANE POTENTIAL; CELL PROLIFERATION; CELL PROTECTION; CHROMOSOMAL INSTABILITY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; GENE EXPRESSION; HUMAN; LIFESPAN; NONHUMAN; PRIORITY JOURNAL; REVIEW;

AGING; ANIMALS; CELL PROLIFERATION; HUMANS; NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 34548179310     PISSN: 14710072     EISSN: 14710080     Source Type: Journal    
DOI: 10.1038/nrm2242     Document Type: Review

References (88)

1. Kirkwood, T. B. & Austad, S. N. Why do we age? Nature 408, 233-238 (2000).
2. Xue, W. et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 445, 656-660 (2007).
3. Collado, M., Blasco, M. A. & Serrano, M. Cellular senescence in cancer and aging. Cell 130, 223-233 (2007).
4. Kirkwood, T. L., Kapahi, P. & Shanley, D. P. Evolution, stress, and longevity. J. Anat. 197, 587-590 (2000).
5. Lesnefsky, E. J. & Hoppel, C. L. Oxidative phosphorylation and aging. Ageing Res. Rev. 5, 402-433 (2006).
6. Bartke, A. Minireview: role of the growth hormone/ insulin-like growth factor system in mammalian aging. Endocrinology 146, 3718-3723 (2005).
7. Guarente, L. Sirtuins as potential targets for metabolic syndrome. Nature 444, 868-874 (2006).
8. Bluher, M., Kahn, B. B. & Kahn, C. R. Extended longevity in mice lacking the insulin receptor in adipose tissue. Science 299, 572-574 (2003).
9. Anisimov, V. N. Insulin/IGF-1 signaling pathway driving aging and cancer as a target for pharmacological intervention. Exp. Gerontol. 38, 1041-1049 (2003).
10. Bordone, L. & Guarente, L. Calorie restriction, SIRT1 and metabolism: understanding longevity. Nature Rev. Mol. Cell Biol. 6, 298-305 (2005).
11. Baur, J. A. & Sinclair, D. A. Therapeutic potential of resveratrol: the in vivo evidence. Nature Rev. Drug Discov. 5, 493-506 (2006).
12. Nemoto, S., Fergusson, M. M. & Finkel, T. Nutrient availability regulates SIRT1 through a fork head dependent pathway. Science 306, 2105-2108 (2004).
13. Rodgers, J. T. et al. Nutrient control of glucose homeostasis through a complex of PGC-1α and SIRT1. Nature 434, 113-118 (2005).
14. Gerhart-Hines, Z. et al. Metabolic control of muscle mitochondrial function and fatty acid oxidation through SIRT1/PGC-1α. EMBO J. 26, 1913-1923 (2007).
15. Baur, J. A. et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 444, 337-342 (2006).
16. Lagouge, M. et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1α. Cell 127, 1109-1122 (2006).
17. Kurosu, H. et al. Suppression of aging in mice by the hormone Klotho. Science 309, 1829-1833 (2005).
18. Greer, E. L. & Brunet, A. FOXO transcription factors at the interface between longevity and tumor suppression. Oncogene 24, 7410-7425 (2005).
19. Anisimov, V. N. Mutant and genetically modified mice as models for studying the relationship between aging and carcinogenesis. Mech. Ageing Dev. 122, 1221-1255 (2001).
20. Hursting, S. D., Lavigne, J. A., Berrigan, D., Perkins, S. N. & Barrett, J. C. Calorie restriction, aging, and cancer prevention: mechanisms of action and applicability to humans. Annu. Rev. Med. 54, 131-152 (2003).
21. Berstein, L. M. Clinical usage of hypolipidemic and antidiabetic drugs in the prevention and treatment of cancer. Cancer Lett. 224, 203-212 (2005).
22. Paik, J. H. et al. FoxOs are lineage-restricted redundant tumor suppressors and regulate endothelial cell homeostasis. Cell 128, 309-323 (2007).
23. Van Remmen, H. & Richardson, A. Oxidative damage to mitochondria and aging. Exp. Gerontol. 36, 957-968 (2001).
24. Pamplona, R. & Barja, G. Mitochondrial oxidative stress, aging and caloric restriction: the protein and methionine connection. Biochim. Biophys. Acta 1757, 496-508 (2006).
25. Dugan, L. L. & Quick, K. L. Reactive oxygen species and aging: evolving questions. Sci. Aging Knowledge Environ. 26, pe20 (2005).
26. Shc generates reactive oxygen species that trigger mitochondrial apoptosis. Cell 122, 221-233 (2005).
27. Schriner, S. E. et al. Extension of murine life span by overexpression of catalase targeted to mitochondria. Science 308, 1909-1911 (2005).
28. Mitsui, A. et al. Overexpression of human thioredoxin in transgenic mice controls oxidative stress and life span. Antioxid. Redox Signal. 4, 693-696 (2002).
29. Golden, T. R., Hinerfeld, D. A. & Melov, S. Oxidative stress and aging: beyond correlation. Aging Cell 1, 117-123 (2002).
30. De Flora, S., Izzotti, A., D'Agostini, F. & Balansky, R. M. Mechanisms of N-acetylcysteine in the prevention of DNA damage and cancer, with special reference to smoking-related end-points. Carcinogenesis 22, 999-1013 (2001).
31. Sablina, A. A. et al. The antioxidant function of the p53 tumor suppressor. Nature Med. 11, 1306-1313 (2005).
32. Reliene, R. & Schiestl, R. H. Antioxidants suppress lymphoma and increase longevity in ATM-deficient mice. J. Nutr. 137 (Suppl. 1), 229-232 (2007).
33. Horn, H. F. & Vousden, K. H. Coping with stress: multiple ways to activate p53. Oncogene 26, 1306-1316 (2007).
34. Toledo, F. & Wahl, G. M. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nature Rev. Cancer 6, 909-923 (2006).
35. Quelle, D. E., Zindy, F., Ashmun, R. A. & Sherr, C. J. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 83, 993-1000 (1995).
36. Sharpless, N. E. INK4a/ARF: a multifunctional tumor suppressor locus. Mutat. Res. 576, 22-38 (2005).
37. Vousden, K. H. & Lane, D. P. p53 in health and disease. Nature Rev. Mol. Cell Biol. 8, 275-283 (2007).
38. Garcia-Cao, I. et al. "Super p53" mice exhibit enhanced DNA damage response, are tumor resistant and age normally. EMBO J. 21, 6225-6235 (2002).
39. Garcia-Cao, I. et al. Increased p53 activity does not accelerate telomere-driven ageing. EMBO Rep. 7, 546-552 (2006).
40. Matheu, A. et al. Increased gene dosage of Ink4a/Arf results in cancer resistance and normal aging. Genes Dev. 18, 2736-2746 (2004).
41. Mendrysa, S. M. et al. Tumor suppression and normal aging in mice with constitutively high p53 activity. Genes Dev. 20, 16-21 (2006).
42. Matheu, A. et al. Delayed aging through damage protection by the Arf/p53 pathway. Nature 448, 375-379 (2007).
43. Tyner, S. D. et al. p53 mutant mice that display early ageing-associated phenotypes. Nature 415, 45-53 (2002).
44. Maier, B. et al. Modulation of mammalian life span by the short isoform of p53. Genes Dev. 18, 306-319 (2004).
45. Pinkston, J. M., Garigan, D., Hansen, M. & Kenyon, C. Mutations that increase the life span of C. elegans inhibit tumor growth. Science 313, 971-975 (2006).
46. Lombard, D. B. et al. DNA repair, genome stability, and aging. Cell 120, 497-512 (2005).
47. Blasco, M. A. Telomeres and human disease: ageing, cancer and beyond. Nature Rev. Genet. 6, 611-622 (2005).
48. de Lange, T. Shelterin: the protein complex that shapes and safeguards human telomeres. Genes Dev. 19, 2100-2110 (2005).
49. Blasco, M. A. The epigenetic regulation of mammalian telomeres. Nature Rev. Genet. 8, 299-309 (2007).
50. Collins, K. & Mitchell, J. R. Telomerase in the human organism. Oncogene 21, 564-579 (2002).
51. Wang, R. C., Smogorzewska, A. & de Lange, T. Homologous recombination generates T-loop-sized deletions at human telomeres. Cell 119, 355-368 (2004).
52. Munoz, P., Blanco, R., Flores, J. M. & Blasco, M. A. XPF nuclease-dependent telomere loss and increased DNA damage in mice overexpressing TRF2 result in premature aging and cancer. Nature Genet. 37, 1063-1071 (2005).
53. Blackburn, E. H., Greider, C. W. & Szostak, J. W. Telomeres and telomerase: the path from maize, Tetrahymena and yeast to human cancer and aging. Nature Med. 12, 1133-1138 (2006).
54. Herbig, U., Ferreira, M., Condel, L., Carey, D. & Sedivy, J. M. Cellular senescence in aging primates. Science 311, 1257 (2006).
55. Shay, J. W. & Wright, W. E. Telomerase therapeutics for cancer: challenges and new directions. Nature Rev. Drug Discov. 5, 577-584 (2006).
56. Gonzalez-Suarez, E. et al. Increased epidermal tumors and increased skin wound healing in transgenic mice overexpressing the catalytic subunit of telomerase, mTERT, in basal keratinocytes. EMBO J. 20, 2619-2630 (2001).
57. Flores, I., Cayuela, M. L. & Blasco, M. A. Effects of telomerase and telomere length on epidermal stem cell behavior. Science 309, 1253-1256 (2005).
58. Sarin, K. Y. et al. Conditional telomerase induction causes proliferation of hair follicle stem cells. Nature 436, 1048-1052 (2005).
59. Muntoni, A. & Reddel, R. R. The first molecular details of ALT in human tumor cells. Hum. Mol. Genet. 14, R191-R196 (2005).
60. Chin, L. et al. p53 deficiency rescues the adverse effects of telomere loss and cooperates with telomere dysfunction to accelerate carcinogenesis. Cell 97, 527-538 (1999).
61. Blanco, R., Munoz, P., Flores, J. M., Klatt, P. & Blasco, M. A. Telomerase abrogation dramatically accelerates TRF2-induced epithelial carcinogenesis. Genes Dev. 21, 206-220 (2007).
62. Zhu, X. D. et al. ERCC1/XPF removes the 3′ overhang from uncapped telomeres and represses formation of telomeric DNA-containing double minute chromosomes. Mol. Cell 12, 1489-1498 (2003).
63. Cawthon, R. M., Smith, K. R., O'Brien, E., Sivatchenko, A. & Kerber, R. A. Association between telomere length in blood and mortality in people aged 60 years or older. Lancet 361, 393-395 (2003).
64. Canela, A., Vera, E., Klatt, P. & Blasco, M. A. High-throughput telomere length quantification by FISH and its application to human population studies. Proc. Natl Acad. Sci. USA 104, 5300-5305 (2007).
65. Coviello-McLaughlin, G. M. & Prowse, K. R. Telomere length regulation during postnatal development and ageing in Mus spretus. Nucleic Acids Res. 25, 3051-3058 (1997).
66. Gonzalez-Suarez, E., Geserick, C., Flores, J. M. & Blasco, M. A. Antagonistic effects of telomerase on cancer and aging in K5-mTert transgenic mice. Oncogene 24, 2256-2270 (2005).
67. Vulliamy, T. et al. Disease anticipation is associated with progressive telomere shortening in families with dyskeratosis congenita due to mutations in TERC. Nature Genet. 36, 447-449 (2004).
68. Choudhury, A. R. et al. Cdkn1a deletion improves stem cell function and lifespan of mice with dysfunctional telomeres without accelerating cancer formation. Nature Genet. 39, 99-105 (2007).
69. Siegl-Cachedenier, I., Muñoz, P., Flores, J. M., Klatt, P. & Blasco, M. A. Deficient mismatch repair improves organismal fitness and survival of mice with dysfunctional telomeres. Genes Dev. in the press.
70. Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D. & Lowe, S. W. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 88, 593-602 (1997).
71. Serrano, M. & Blasco, M. A. Putting the stress on senescence. Curr. Opin. Cell Biol. 13, 748-753 (2001).
72. Collado, M. et al. Tumour biology: senescence in premalignant tumours. Nature 436, 642 (2005).
73. Chen, Z. et al. Crucial role of p53-dependent cellular senescence in suppression of PTEN-deficient tumorigenesis. Nature 436, 725-730 (2005).
74. Michaloglou, C. et al. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 436, 720-724 (2005).
75. Krishnamurthy, J. et al. Ink4a/Arf expression is a biomarker of aging. J. Clin. Invest. 114, 1299-1307 (2004).
76. Ressler, S. et al. p16INK4A is a robust in vivo biomarker of cellular aging in human skin. Aging Cell 5, 379-389 (2006).
77. Gil, J. & Peters, G. Regulation of the INK4b-ARF-INK4a tumour suppressor locus: all for one or one for all. Nature Rev. Mol. Cell Biol. 7, 667-677 (2006).
78. Bracken, A. P. et al. The Polycomb group proteins bind throughout the INK4A-ARF locus and are disassociated in senescent cells. Genes Dev. 21, 525-530 (2007).
79. Janzen, V. et al. Stem-cell ageing modified by the cyclin-dependent kinase inhibitor p16INK4a. Nature 443, 421-426 (2006).
80. Krishnamurthy, J. et al. p16INK4a induces an age-dependent decline in islet regenerative potential. Nature 443, 453-457 (2006).
81. Molofsky, A. V. et al. Increasing p16INK4a expression decreases forebrain progenitors and neurogenesis during ageing. Nature 443, 448-452 (2006).
82. Cheng, T. et al. Hematopoietic stem cell quiescence maintained by p21cip1/waf1. Science 287, 1804-1808 (2000).
83. Gentry, A. & Venkatachalam, S. Complicating the role of p53 in aging. Aging Cell 4, 157-160 (2005).
84. Gudmundsdottir, K. & Ashworth, A. The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability. Oncogene 25, 5864-5874 (2006).
85. Cao, L., Li, W., Kim, S., Brodie, S. G. & Deng, C. X. Senescence, aging, and malignant transformation mediated by p53 in mice lacking the BRCA1 full-length isoform. Genes Dev. 17, 201-213 (2003).
86. Varela, I. et al. Accelerated ageing in mice deficient in ZMPSTE24 protease is linked to p53 signalling activation. Nature 437, 564-568 (2005).
87. Liu, B. et al. Genomic instability in laminopathy-based premature aging. Nature Med. 11, 780-785 (2005).
88. Flores, I., Benetti, R. & Blasco, M. A. Telomerase regulation and stem cell behaviour. Curr. Opin. Cell Biol. 18, 254-260 (2006).